Representatives of Vietnam Medical Association and Pfizer Vietnam sign a Memorandum of Understanding on April 17. — Photo courtesy of VMA

HÀ NỘI — The Vietnam Medical Association (VMA) and Pfizer Vietnam will collaborate across multiple therapeutic areas to improve the quality of healthcare in Việt Nam as part of a Memorandum of Understanding signed on April 17.

The cooperation aims to enhance the effectiveness of antimicrobial resistance management, as mentioned in the National Strategy on Antimicrobial Resistance Control 2023 – 2030, with a vision to 2045.

It builds on Pfizer's expertise in pharmaceuticals and its resources, along with the VMA's close engagement and deep understanding of the role of hospitals and government management units in the fight against the growing threat of antimicrobial resistance.

“The Memorandum of Understanding with Pfizer Vietnam marks a milestone in the co-operation among stakeholders to jointly improve the quality of healthcare for the people. We hope to have a positive impact with our joint initiatives through the specific programs mentioned,” said President of the Vietnam Medical Association Nguyễn Thị Xuyên.

Following the COVID-19 pandemic, collaborative efforts between prevention and treatment in managing respiratory diseases have emerged as a priority. Together, VMA and Pfizer Vietnam have committed to providing expertise and resources to each other to enhance the opportunity for patients to access new prevention solutions and new medicines for the management of respiratory infections.

In addition, both parties have also committed to continuing co-operation, exchange, and support in updating medical information and knowledge for healthcare professionals. This is important for enhancing the capability of healthcare professionals to ensure the health and welfare of the Vietnamese people.

To achieve the above mutually aligned goals, the project is designed to enhance healthcare outcomes through a series of joint initiatives, including collaboration in supporting and sponsoring scientific activities for relevant scientific information in healthcare and health policy/management; collaborations with relevant healthcare organisations to support the hospital sector in implementing the antimicrobial resistance management programme, AMS, thus enhancing the capability of clinical microbiology, clinical pharmacology and clinicians in the appropriate use of antibiotics; and collaborate with relevant organisations to improve the prevention, diagnosis, and treatment capability of respiratory diseases.

“We are delighted to partner with the Vietnam Medical Association to address critical healthcare challenges in Việt Nam," said Darrell Oh, General Director of Pfizer Vietnam. "Both AMR and respiratory illnesses are of immediate concern to society at large and I believe that these efforts will yield tangible benefits in both governance and patient health.” — VNS